Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News Roundup: Drug Makers Take Steps To Minimize Impact Of Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth, King update investors on generic Protonix, Skelaxin, while Ranbaxy wins tentative ANDA approval of Nexium generics.

You may also be interested in...



Teva Wins One, Loses One In Patent Challenge Appeals At The Federal Circuit

P&G's Actonel patent ruled valid: The U.S. Court of Appeals for the Federal Circuit rejected Teva's claims that the patent covering the active ingredient in Actonel (risedronate) was obvious and thus invalid. The court upheld a lower court decision that the unexpected results of the drug's potency and toxicity rebut Teva's claim that it was obvious to develop risedronate based on its similarity to another compound. P&G markets the osteoporosis drug in collaboration with Sanofi-Aventis. Actonel had more than $1 billion sales in 2008. The composition patent extends through June 2014 with the pediatric extension P&G received last month

Teva Wins One, Loses One In Patent Challenge Appeals At The Federal Circuit

P&G's Actonel patent ruled valid: The U.S. Court of Appeals for the Federal Circuit rejected Teva's claims that the patent covering the active ingredient in Actonel (risedronate) was obvious and thus invalid. The court upheld a lower court decision that the unexpected results of the drug's potency and toxicity rebut Teva's claim that it was obvious to develop risedronate based on its similarity to another compound. P&G markets the osteoporosis drug in collaboration with Sanofi-Aventis. Actonel had more than $1 billion sales in 2008. The composition patent extends through June 2014 with the pediatric extension P&G received last month

Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field

Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel